Credit Suisse | GenomeWeb

Credit Suisse

NEW YORK (GenomeWeb News) – Credit Suisse today upgraded Myriad Genetics' stock and raised the price target on its shares, while it downgraded Genomic Health and lowered the price target on that firm's shares.

NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today upgraded shares of Sequenom to Neutral, noting the non-invasive prenatal fetal aneuploidy testing firm's announcement of its national contract with

NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today initiated coverage of Agilent Technologies with an Outperform rating and a $48 price target.

NEW YORK (GenomeWeb News) – Credit Suisse on Monday initiated coverage of Genomic Health with an Outperform rating, Myriad Genetics with a Neutral rating, and Sequenom with an Underperform rating.

NEW YORK (GenomeWeb News) – Investment bank Credit Suisse today upgraded Illumina's stock, citing the firm's improved financial performance over the past two quarters and the potential of its tools for the clinical market in the longer term.

The firm launched three microRNA-based tests during the fourth quarter, and posted a profit due to a capital gain on the sale of Auction Rate Securities to Credit Suisse. However, Rosetta only has enough cash to fund operations through mid-2010 and said that it may seek to raise additional funds.

Agilent's shares soared along with the broader market on Monday, while Celera's stock dropped. Even though an analyst upgraded the stock, he also lowered his revenues and EPS estimates for the firm.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.